British Prime Minister Keir Starmer arrived in Shanghai Friday with over 50 business leaders, aiming to deepen UK-China commercial ties. The visit, the first by a UK premier in eight years, comes against a backdrop of renewed US skepticism over Western engagement with Beijing.
Bitcoin's volatility gauge spiked sharply during Thursday's sell-off, signaling heightened trader anxiety and a rush for downside protection, though metrics suggest the market is not yet in extreme fear territory.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
The utility giant Southern Company has declared its latest quarterly dividend, preserving one of corporate America's most remarkable records of shareholder returns. As markets fluctuate, the company's steady income stream and undervalued stock price are drawing renewed attention from long-term investors.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
Shares of the building products manufacturer have retreated from recent highs, presenting investors with a valuation puzzle. While a key cash flow model suggests the stock is undervalued, its premium P/E ratio tells a more cautious story. We break down the conflicting signals.
Standex International Corporation reported robust fiscal second-quarter results, with revenue climbing to $221.32 million and net income reaching $2.12 million. The company raised its quarterly dividend by 6.3% and issued an upbeat forecast for the third quarter, reinforcing confidence in its strategic shift toward high-value engineered products.
German industrial giant Thyssenkrupp is exploring the sale of a significant minority stake in its Rothe Erde bearings division, a move analysts say could signal a broader portfolio reshuffle and highlight persistent valuation gaps within the conglomerate.
Krones AG (ETR:KRN) has seen its stock price climb 11% in the past quarter. Analysis points to robust fundamentals, particularly a healthy Return on Equity (ROE) of 14%, as a key driver behind the market's bullish sentiment and the company's impressive earnings growth trajectory.
The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.
United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.
Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
As the FTSE indices reel from weak Chinese trade data, a screen of undervalued UK equities reveals potential opportunities. We examine three companies trading significantly below their estimated cash flow value.
Despite bearing the brunt of costly natural disasters, Asia-Pacific remains the world's least insured region, with a staggering $64 billion protection shortfall in 2024 alone, threatening economic stability and vulnerable communities.
Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.
